The capsule polysaccharide from serogroups A, B, C, W, and Y meningococci inhibits C1q interaction with bound anti-fHbp and anti-porin A antibodies, and, consequently, the deposition of C4b and classical complement pathway (Jarvis and Vedros, 1987), as well as LOS sialylation (Vogel et al., 1997), limits C3 deposition, inhibiting the alternative pathway
Baseline kidney function testing before initiating either substance, with periodic monitoring based on individual risk factors, represents prudent clinical practice, particularly in patients with diabetes or other kidney disease risk factors
For most people, the relevant answer is about topical timing
doi:10.1111/j.1471-4159.2006.03913.x
This is your skincare ritual, upgraded
Ashkar H et al (2024): Dobutamine